- Report
- September 2024
- 97 Pages
Global
From €4187EUR$4,850USD£3,627GBP
- Directory
- August 2022
- 1046 Pages
Japan
From €8589EUR$9,950USD£7,441GBP
- Report
- December 2022
- 2271 Pages
Global
From €2158EUR$2,500USD£1,870GBP
- Report
- October 2022
- 94 Pages
Global
From €1726EUR$2,000USD£1,496GBP
- Report
- October 2022
- 532 Pages
Global
From €2158EUR$2,500USD£1,870GBP
- Report
- October 2025
- 92 Pages
Global
From €3500EUR$4,343USD£3,138GBP
- Report
- October 2023
- 80 Pages
Global
From €3500EUR$4,343USD£3,138GBP
- Report
- May 2023
- 113 Pages
Global
From €3500EUR$4,343USD£3,138GBP
- Report
- January 2025
- 132 Pages
Global
From €820EUR$950USD£710GBP

Prodrugs are a type of biotechnology that involves the modification of a drug molecule to improve its pharmacokinetic properties. This is done by making the drug more soluble, increasing its absorption, or making it more stable in the body. Prodrugs are designed to be more effective and safer than the original drug, and can be used to treat a variety of diseases.
Prodrugs are used in a variety of therapeutic areas, including cancer, cardiovascular disease, and infectious diseases. They are also used to improve the delivery of drugs to specific tissues or organs, and to reduce the side effects of drugs.
The prodrug market is growing rapidly, driven by the increasing demand for more effective and safer drugs. The market is expected to continue to grow in the coming years, as more companies develop and launch new prodrugs.
Some companies in the prodrug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more